We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
-9.83%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$370M
AUM Growth
+$33.7M
Cap. Flow
+$5.67M
Cap. Flow %
1.54%
Top 10 Hldgs %
68.63%
Holding
64
New
13
Increased
12
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$16.2M
2
SNN icon
Smith & Nephew
SNN
+$14.5M
3
VXRT
Vaxart
VXRT
+$12.3M
4
ZBH icon
Zimmer Biomet
ZBH
+$9.56M
5
ABT icon
Abbott
ABT
+$9.49M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$21.1M
2
CI icon
Cigna
CI
+$17M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.6M
4
MDT icon
Medtronic
MDT
+$9.15M
5
EMBC icon
Embecta
EMBC
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 69.35%
2 Miscellaneous 28.26%
3 Consumer Staples 2.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
PUT
Insmed
INSM
$25.9B
$91.3M 24.71%
1,362,700
– –
LH icon
2
Labcorp
LH
$27.2B
$50M 13.54%
245,902
+20,000
+9% +$4.07M
TFX icon
3
Teleflex
TFX
$5.92B
$23.4M 6.32%
111,078
+77,200
+228% +$16.2M
ZBH icon
4
Zimmer Biomet
ZBH
$19.2B
$16.9M 4.56%
155,304
+81,125
+109% +$9.56M
SNN icon
5
Smith & Nephew
SNN
$12.1B
$14.4M 3.89%
+579,619
New +$14.5M
PCRX icon
6
PUT
Pacira BioSciences
PCRX
$1.03B
$13M 3.53%
455,500
+343,500
+307% +$9.78M
OGN icon
7
Organon & Co
OGN
$3.61B
$12.6M 3.41%
608,096
+129,073
+27% +$2.57M
GSK icon
8
GSK
GSK
$102B
$12M 3.25%
312,000
+48,555
+18% +$2.04M
CRBP icon
9
Corbus Pharmaceuticals
CRBP
$211M
$10.2M 2.76%
+225,165
New +$9.47M
VXRT
10
DELISTED
Vaxart
VXRT
$9.85M 2.67%
+14,764,991
New +$12.3M
TYRA icon
11
Tyra Biosciences
TYRA
$1.49B
$9.6M 2.6%
600,294
+64,553
+12% +$1.11M
ABT icon
12
Abbott
ABT
$195B
$9.3M 2.52%
+89,500
New +$9.49M
CI icon
13
Cigna
CI
$73.7B
$8.85M 2.4%
26,786
-49,300
-65% -$17M
KVUE icon
14
Kenvue
KVUE
$36.8B
$8.82M 2.39%
+485,000
New +$9.4M
IRON icon
15
Disc Medicine
IRON
$3.07B
$8.65M 2.34%
+192,000
New +$6.52M
ERAS icon
16
Erasca
ERAS
$6.31B
$6.78M 1.84%
2,874,536
+447,352
+18% +$965K
BDSX icon
17
Biodesix
BDSX
$283M
$6.65M 1.8%
+217,393
New +$6.21M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$4.64M 1.26%
510,267
+100,000
+24% +$976K
ANIP icon
19
ANI Pharmaceuticals
ANIP
$1.67B
$4.57M 1.24%
71,740
-15,614
-18% -$1.01M
BLCO icon
20
Bausch + Lomb
BLCO
$6.13B
$4.4M 1.19%
+302,710
New +$4.55M
PMVP icon
21
PMV Pharmaceuticals
PMVP
$65.2M
$4.39M 1.19%
+2,708,408
New +$4.88M
ZYME icon
22
Zymeworks
ZYME
$2.02B
$4.18M 1.13%
+491,128
New +$4.37M
BBIO icon
23
BridgeBio Pharma
BBIO
$15B
$3.17M 0.86%
125,174
-78,000
-38% -$2.13M
APGE icon
24
Apogee Therapeutics
APGE
$10.2B
$3.07M 0.83%
78,000
– –
CNTX icon
25
Context Therapeutics
CNTX
$35.3M
$2.66M 0.72%
+1,328,352
New +$2.29M
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sio Capital Management held 64 positions worth $370M, up 10% from $336M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sio Capital Management's Q2 2024 filing shows 13 new, 12 increased, 8 reduced and 16 closed positions. Its largest new stake was Smith & Nephew: 579,619 shares worth $14.4M. The largest sale was Globus Medical, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Sio Capital Management's largest Q2 2024 buy was Smith & Nephew: 579,619 shares worth $14.4M.
  • Sio Capital Management added most to Teleflex in Q2 2024, an estimated $16.2M increase.
  • Sio Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $17M.
  • Sio Capital Management fully exited Globus Medical in Q2 2024, selling an estimated $21.1M.
  • Sio Capital Management's ten largest holdings make up 69% of its $370M portfolio in Q2 2024.
  • Sio Capital Management opened 13 new positions and closed 16 in Q2 2024.
  • Sio Capital Management's portfolio value rose 10% quarter-over-quarter to $370M.

Based on Sio Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.